Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages 59-63

  Castelnuovo, Barbara ^a   Kiragga, Agnes ^a   Kamya, Moses R ^a   Manabe, Yukari ^a,b  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MULTIVARIATE ANALYSIS; NEVIRAPINE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; STAVUDINE; UGANDA; ZIDOVUDINE;

EID: 78650697283     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f5bd03     Document Type: Article

References (34)

1. Corey DM, Kim HW, Salazar R, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007;44:451-455.
2. Laurent C, Ngom Gueye NF, Ndour CT, et al, and ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38: 14-17.
3. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008;168:86-93.
4. Toure S, Kouadio B, Seyler C, et al, and Aconda Study Group. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cöte d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882.
5. Van Der Borght SF, Clevenbergh P, Rijckborst H, et al. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Antivir Ther. 2009; 14:63-74.
6. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2203-2011.
7. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral (HAART) regimen in a cohort of antiretroviral nä?ve patients. AIDS. 1999;14:499-507.
8. Grant LA, Silverberg MJ, Palacio H, et al. Discontinuation if potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001;15:2101-2108.
9. Lodwick R, Smith CJ, Youle F, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS. 2008;22:1039-1046.
10. O'Brien ME, Clark R, Besh L. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
11. Campaign for Access to Essential Medicines, Medecins Sans Frontieres. Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries. 9th ed. Geneva, Switzerland: Medecins Sans Frontieres; 2006.
12. WHO. National Antiretroviral Treatment and Care Guidelines for Adults and Children. 1st ed. Kampala, Uganda: Ministry of Health, Republic of Uganda; 2003.
13. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006. Available at: http:// www.who.int/hiv/pub/guidelines/art/en/index.html. Accessed May 5, 2008.
14. Dragovic G, Jevtovic D. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy. Antivir Chem Chemother. 2003;14:281-284.
15. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
16. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
17. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related syndrome. AIDS. 2000;18: F25-F32.
18. WHO. Tracking HIV drug resistance in facilities providing antiretroviral therapy in Uganda. Kampala, Uganda September 2009.
19. Venter F. When to start in resource-poor areas. Presented at: 5th IAS Conference on HIV pathogenesis, Treatment and prevention; July 19-22, 2009; Cape Town, South Africa. MOSY103.
20. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44:456-462.
21. Hawkins C, Achenbach C, Fryda W, et al. antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 45:304-310.
22. Kumarasamy N, Vallhabaneni S, Cecelia AJ, et al. Reason for modification of generic highly active antiretroviral therapeutic regimen among patients in Southern India. J Acquir Immune Defic Syndr. 2006;41: 53-58.
23. Sivadasan A, Abraham OC, Rupali P, et al. High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India. 2009;57:384-388.
24. Boulle A, Orrell C, Kaplan R, et al. Substitution due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12:753-760.
25. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. Plos Med. 2008;5:e148.
26. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193.
27. WHO 2003. World Health Organization (2003). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/3by5/publications/documents/arv-guidelines/ en/index.html. Accessed July 28, 2009.
28. WHO. Addendum to 2006 WHO guidelines on antiretroviral treatment therapy for HIV infection in adults and adolescents. Available at: http:// www.who.int/hiv/art/ARTadultsaddendum.pdf. Accessed February 15, 2010.
29. Castelnuovo B, Manabe Y, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first three years after antiretroviral therapy in an urban African cohort. Clin Infect Dis. 2009;49:965-972.
30. Wester CM, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana. Preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007;46:318-322.
31. Lactic acidosis international group. Risk factors for severe lactic acidosis and hyperlactatemia in HIV-1 infected adults exposed to antiretroviral treatment. AIDS. 2007;21:2455-2464.
32. Weistreich D, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009;48:1617-1623.
33. Kamya M, Kiragga A, Castelnuovo B. Four-year treatment outcome for antiretroviral therapy in a cohort of adult patients, Kampala, Uganda. Presented at: 5th IAS Conference on HIV pathogenesis, Treatment and prevention; 2009; Cape Town, South Africa. MOPEB052.
34. Pujades-Rodŕ?guez M, Humblet P, Balkan S, et al. Reported severe toxicity during 36 months of ART: a multicentric longitudinal study in nineteen African and Asian HIV/AIDS programmes. Presented at: XV International Conference on AIDS and STIs in Africa 2008. Dakar, Uttarakhand. 94/SOB103.